$8.93
6.10% day before yesterday
NYSE, May 30, 10:10 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$8.93
+0.18 2.06% 1M
-7.01 43.98% 6M
-5.96 40.03% YTD
-6.00 40.19% 1Y
-10.26 53.47% 3Y
-24.11 72.97% 5Y
-8.07 47.47% 10Y
NYSE, Closing price Fri, May 30 2025
-0.58 6.10%
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Key metrics

Market capitalization $945.55m
Enterprise Value $-3.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.01
EV/Sales (TTM) EV/Sales -0.02
P/S ratio (TTM) P/S ratio 6.71
P/B ratio (TTM) P/B ratio 1.78
Revenue growth (TTM) Revenue growth -40.51%
Revenue (TTM) Revenue $141.00m
EBIT (operating result TTM) EBIT $-436.00m
Free Cash Flow (TTM) Free Cash Flow $-303.00m
Cash position $997.00m
EPS (TTM) EPS $-3.98
P/E forward negative
P/S forward 7.42
EV/Sales forward negative
Short interest 14.34%
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Arcus Biosciences forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Arcus Biosciences forecast:

Buy
83%
Hold
17%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
141 141
41% 41%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
3% 3%
82%
- Research and Development Expense - -
-
-
-426 -426
77% 77%
-302%
- Depreciation and Amortization 10 10
11% 11%
7%
EBIT (Operating Income) EBIT -436 -436
74% 74%
-309%
Net Profit -391 -391
69% 69%
-277%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
4 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 13,400 shares of the Company's comm...
Neutral
Business Wire
22 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's co...
Neutral
Seeking Alpha
25 days ago
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob Goeltz - CFO Juan Jaen - President Conference Call Participants Peter Lawson - Barclays Daina Graybosch - Leerink Partners Yigal Nochomovitz - Citigroup Umer Raffat - Evercore Eva Fortea - Wells Far...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 627
Founded 2015
Website arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today